Metavia INC 10-Q quarterly reports

MetaVia Inc. reported increased R&D expenses and a widening net loss for Q2 2026, while acknowledging substantial doubt about its ability to continue as a going concern.

MetaVia Inc. reported a net loss of $3.8 million for Q1 2026, with operating expenses increasing slightly, while cash reserves remain a concern for ongoing operations.

MetaVia Inc. reports reduced net losses but raises substantial doubt about its ability to continue as a going concern, despite positive clinical trial updates for its cardiometabolic drug candidates.

MetaVia Inc. reported a significant reduction in net loss for Q2 2025, driven by decreased R&D expenses, and secured $9.1 million in net proceeds from a private placement, though a going concern warning persists.

MetaVia Inc. announces its Q1 2025 financial results, showcasing a decrease in net loss compared to the previous year and providing updates on its DA-1241 and DA-1726 clinical trials.

NeuroBo Pharmaceuticals' Q3 2024 report reveals a significant increase in research and development expenses as the company advances its clinical trials for MASH and obesity treatments.

NeuroBo Pharmaceuticals' Q2 2024 report reveals a significant increase in research and development expenses due to ongoing clinical trials for their MASH and obesity treatments, alongside a recent $20 million capital raise.

NeuroBo Pharmaceuticals reported a net loss of $6.7 million for the first quarter of 2024, while advancing its clinical programs for MASH and obesity.